“FDA cleared” and “FDA approved” sound interchangeable, but they represent two different regulatory pathways with very different levels of scrutiny. The distinction comes down to device risk: cleared devices go through a shorter process that compares them to something already on the market, while approved devices undergo a rigorous independent review including clinical trials. Understanding which label a product carries tells you a lot about how much evidence the FDA reviewed before allowing it to be sold.
What “FDA Cleared” Actually Means
When a device is FDA cleared, it has gone through a process called 510(k) premarket notification. The manufacturer submits evidence showing their device is “substantially equivalent” to a device that’s already legally sold in the United States. That existing device is called a predicate. The comparison looks at whether the new device has the same intended use and the same (or similar) technological characteristics as the predicate.
Substantial equivalence doesn’t mean identical. The new device can differ from the predicate in design or materials, as long as those differences don’t raise new safety concerns. To support their case, manufacturers can submit bench testing, engineering performance data, biocompatibility evaluations, and sometimes clinical data, though clinical trials aren’t always required. The FDA reviews this evidence and decides whether the device is as safe and effective as the one it’s being compared to.
This pathway covers most Class II medical devices, which the FDA considers moderate to high risk. Think of things like powered wheelchairs, pregnancy tests, contact lenses, and surgical drapes. These products go to market based on their similarity to predecessors, not on standalone proof that they work.
What “FDA Approved” Actually Means
FDA approval requires a Premarket Approval application, or PMA. This is the most stringent review process the FDA uses for medical devices. Rather than comparing a device to something already on the market, the manufacturer must independently prove the device is safe and effective through valid scientific evidence.
A PMA application includes both non-clinical laboratory studies (covering things like toxicology, biocompatibility, stress testing, and shelf life) and clinical investigations with human subjects. The clinical section must include study protocols, safety and effectiveness data, adverse reactions, device failures, individual patient data, and statistical analyses. The FDA reviews all of this before making its decision, and the agency has 180 days from the filing date to complete its review.
This pathway applies to Class III devices, the highest-risk category. Class III includes devices that sustain or support human life, play a critical role in preventing serious health problems, or present a potential unreasonable risk of illness or injury. Examples include implantable pacemakers, heart valves, and breast implants. These devices cannot be sold until the FDA grants explicit approval.
The Core Difference: Comparison vs. Proof
The fundamental distinction is what the manufacturer has to demonstrate. For clearance, the question is: “Is this device similar enough to something we already allow?” For approval, the question is: “Does the evidence prove this device is safe and effective on its own merits?”
Clearance is built on a chain of equivalence. A new device points to a predicate, which may itself have pointed to an earlier predicate. The system assumes that if the original device was safe enough to sell, and the new one is substantially similar, the new one is also safe enough. This works well for incremental improvements to established technology, but critics have pointed out that devices can drift significantly from the original over many generations of predicates.
Approval, by contrast, requires the manufacturer to build a case from scratch with clinical trial data. There’s no shortcut through comparison. The FDA evaluates the evidence independently and decides whether the device meets the bar for safety and effectiveness. This takes longer and costs significantly more, but produces a much thicker body of evidence before the device reaches patients.
How Device Risk Classes Map to Each Pathway
The FDA assigns every medical device to one of three classes based on how much regulatory control is needed to ensure safety:
- Class I (low to moderate risk): Subject to general controls like proper labeling and manufacturing standards. Many Class I devices are exempt from the 510(k) process entirely. Examples include bandages, tongue depressors, and handheld surgical instruments.
- Class II (moderate to high risk): Subject to general controls plus special controls, which can include performance standards, postmarket surveillance, or specific labeling requirements. Most Class II devices require 510(k) clearance.
- Class III (high risk): Subject to general controls plus Premarket Approval. These devices need the full PMA process with clinical evidence.
The class assignment drives which pathway a manufacturer must follow. You don’t get to choose clearance over approval to save time. If your device is Class III, it requires PMA approval unless the FDA has specifically downclassified it.
The De Novo Pathway: A Middle Ground
Sometimes a new device is novel enough that no predicate exists, but the risk level doesn’t warrant the full PMA process. The De Novo classification request fills this gap. It allows manufacturers to ask the FDA to classify a novel device into Class I or Class II based on a risk evaluation, even without a predicate device to compare against.
A manufacturer can submit a De Novo request either after receiving a “not substantially equivalent” determination from a 510(k) submission, or directly if they already know there’s no suitable predicate. Once the FDA grants a De Novo request and classifies the device, it can serve as a predicate for future 510(k) submissions by other companies. Many first-of-their-kind consumer health devices, like certain wearable monitors, have entered the market through this route.
Why the Wording Matters on Products You Buy
Companies know that “FDA” in any context sounds reassuring, and the precise wording on a product label carries real legal meaning. A product labeled “FDA approved” should have gone through the PMA process with clinical data. A product labeled “FDA cleared” went through the 510(k) pathway based on substantial equivalence to a predicate.
There’s a third term that causes even more confusion: “FDA registered.” Registration simply means a manufacturer has listed its establishment and devices with the FDA, which is a legal requirement for anyone making or distributing medical devices in the U.S. It does not mean the FDA has reviewed the device for safety or effectiveness. Some companies use “FDA registered” in marketing to imply a level of government endorsement that doesn’t exist.
When you see these terms on a product, the hierarchy of scrutiny runs from registered (least) to cleared (moderate) to approved (most). A product that’s only “registered” has not been evaluated by the FDA at all. A cleared product has been compared to an existing device. An approved product has been independently proven safe and effective through clinical evidence. Knowing that distinction helps you judge how much weight to give the claim on the box.